Results 141 to 150 of about 807 (164)
Some of the next articles are maybe not open access.
Azvudine and mortality in patients with coronavirus disease 2019: A retrospective cohort study
International Immunopharmacology, 2023Several studies have found that azvudine (FNC) can inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication both in vivo and in vitro. However, the effect of FNC on the risk of death in patients with coronavirus disease 2019 (COVID-19) is unclear.
Bin Liu +7 more
openaire +2 more sources
A Nearly
Comprehensive SummaryModified nucleosides, particularly those with 4'‐modifications, are significant nucleosides used in antiviral treatments. The drug discovery campaign of Azvudine starts from 2′‐deoxynucleoside, followed by extensive modifications, such as introducing the 4’‐position substitutions, a 2’‐β‐fluoro atom, and changing the nucleobases ...
Bin Yu, Junbiao Chang
openaire +1 more source
Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis
Reviews in Medical VirologyAbstractThis systematic review and meta‐analysis aimed to compare the effectiveness and safety of azvudine versus nirmatrelvir/ritonavir (Paxlovid) in treating coronavirus disease 2019 (COVID‐19). The researchers conducted searches on PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until January 2024.
Behnam Amani, Bahman Amani
exaly +3 more sources
Separation and quantification of Azvudine in plasma of patients with COVID-19 using LC-MS/MS
Journal of Pharmaceutical and Biomedical Analysis, 2023Azvudine (FNC) is a new drug conditionally approved in 2022 for the treatment of coronavirus disease 2019 (COVID-19) in China. However, the exposure level of FNC in COVID-19 patients in clinical practice is still obscure, and there is no liquid chromatography-tandem mass spectrometry (LC-MS/MS) or LC method reported for quantifying the FNC.
Zhijun Liu +8 more
openaire +2 more sources
A Retrospective Study on Azvudine in Hospitalized Elderly Patients with COVID-19
CoronavirusesBackground: The ongoing 2019 novel coronavirus pneumonia pandemic continues to pose a serious threat to public health and safety. In response, numerous specific anti-SARS-CoV-2 drugs have been urgently approved for use. Azvudine has been recommended as a priority treatment for COVID-19 patients, but its efficacy and safety in elderly patients remain ...
Ruifang Nie +4 more
openaire +1 more source
Real‐world effectiveness of azvudine: Elixir or equivocal answer?
Journal of Medical Virology, 2023Yuan Gao +3 more
openaire +2 more sources
Evaluate clinical effectiveness of Azvudine with data rather than speculation
Journal of Medical Virology, 2023Guangtong Deng +3 more
openaire +2 more sources
Abstract 3866: Azvudine: An emerging immunomodulator in the treatment of cancer and viral infections
Cancer ResearchAbstract Azvudine (FNC) is a nucleoside analog that has secured approval from the CDE in China for the treatment of both AIDS and COVID-19. In these contexts, it has showed remarkable efficacy and safety when taken orally. Typically, nucleoside analog drugs function by integrating into DNA and impeding DNA synthesis, evident in drugs ...
Pan Li +3 more
openaire +1 more source